Windtree Therapeutics (WINT) Stock Price, News & Analysis

Company Overview

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular and pulmonary diseases. The company’s proprietary technology platforms include the KL4 surfactant formulation and the Aerosurf® (formerly AeriSeal®) polymer foam technology, both designed to address critical conditions such as neonatal respiratory distress syndrome (nRDS), acute respiratory distress syndrome (ARDS), and alveolar leaks associated with mechanical ventilation. By combining expertise in lipid science, pulmonary delivery, and critical care medicine, Windtree aims to fill unmet medical needs across a range of acute and life-threatening indications. Windtree’s product pipeline is anchored by its lead asset, KL4 surfactant, which is being evaluated for the prevention and treatment of nRDS in premature infants and for inflammatory lung diseases in adults. The Aerosurf polymer foam technology is engineered to seal alveolar air leaks and has potential applications in critical care settings, including ARDS and bronchopleural fistulas. In addition to these core programs, the company has initiated exploratory studies for potential treatments of pulmonary alveolar proteinosis and other rare lung disorders. Since its founding in 2006 and subsequent public listing on the NASDAQ under the ticker WINT, Windtree has maintained headquarters in Warrington, Pennsylvania, with research collaborations and clinical trial sites across North America, Europe, and Asia. The company leverages strategic partnerships with academic institutions, contract research organizations, and healthcare providers to support its global clinical development activities. Windtree’s management team brings together seasoned professionals from the pharmaceutical and biotechnology sectors. The company is led by Chief Executive Officer Robert Pangia, whose prior roles include senior leadership positions at specialty pharma and medical device companies. The board of directors comprises independent members with deep expertise in drug development, regulatory affairs, and commercial strategy. Together, Windtree’s leadership is committed to advancing its portfolio through late-stage clinical trials and toward potential regulatory approvals.

Key Stats

• Today's Range: $1.09 to $1.35
• 50-Day Range: $0.37 to $1.19
• 52-Week Range: $0.36 to $737.44
• Volume: 19.25 million shs
• Average Volume: 3.20 million shs
• Market Capitalization: $4.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $350.00
• Consensus Rating: Hold

Windtree Therapeutics Stock Analysis - MarketRank™

Windtree Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Windtree Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Windtree Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Windtree Therapeutics are expected to grow in the coming year, from ($5.66) to ($2.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Windtree Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Windtree Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Windtree Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.43% of the float of Windtree Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Windtree Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Windtree Therapeutics has recently decreased by 82.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Windtree Therapeutics does not currently pay a dividend.

Dividend Growth

Windtree Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.43% of the float of Windtree Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Windtree Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Windtree Therapeutics has recently decreased by 82.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.75

News Sentiment

Windtree Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Windtree Therapeutics this week, compared to 2 articles on an average week.

Search Interest

30 people have searched for WINT on MarketBeat in the last 30 days. This is an increase of 2,900% compared to the previous 30 days.

MarketBeat Follows

3 people have added Windtree Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.33% of the stock of Windtree Therapeutics is held by insiders.

Percentage Held by Institutions

Only 29.33% of the stock of Windtree Therapeutics is held by institutions.

WINT Stock Analysis - Frequently Asked Questions

How have WINT shares performed this year?

Windtree Therapeutics' stock was trading at $17.4650 on January 1st, 2025. Since then, WINT shares have decreased by 93.2% and is now trading at $1.19.

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) released its quarterly earnings results on Thursday, May, 15th. The company reported ($4.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($39.00) by $34.37.

When did Windtree Therapeutics' stock split?

Windtree Therapeutics's stock reverse split on the morning of Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Windtree Therapeutics?

Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WINT
• CIK: 946486
• Web: www.windtreetx.com
• Phone: (215) 488-9300
• Fax: 215-488-9301
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Windtree Therapeutics: $350.00
• High Price Target: $350.00
• Low Price Target: $350.00
• Potential Upside/Downside: +29,311.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($823.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -227.93%
• Return on Assets: -56.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.25
• Quick Ratio: 0.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $38.99 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 3,660,000
• Free Float: 3,649,000
• Market Cap: $4.36 million
• Optionable: Not Optionable
• Beta: 0.70